100 related articles for article (PubMed ID: 1806033)
1. Interaction of melphalan and dexamethasone in a human myeloma cell line.
Fernberg JO; Lewensohn R; Skog S
Anticancer Drugs; 1991 Dec; 2(6):565-70. PubMed ID: 1806033
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226.
Fernberg JO; Lewensohn R; Skog S
Eur J Haematol; 1991 Sep; 47(3):161-7. PubMed ID: 1915798
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
6. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
7. Interphase cell death as related to the cell cycle of melphalan-treated human myeloma cells.
Fernberg JO; Lewensohn R; Skog S
Med Oncol Tumor Pharmacother; 1991; 8(2):63-7. PubMed ID: 1749301
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines.
Hjertner O; Börset M; Waage A
Leuk Res; 1996 Feb; 20(2):155-60. PubMed ID: 8628014
[TBL] [Abstract][Full Text] [Related]
9. Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma.
Zaffaroni N; Villa R; Orlandi L; Vaglini M; Silvestrini R
Int J Hyperthermia; 1992; 8(3):341-9. PubMed ID: 1607739
[TBL] [Abstract][Full Text] [Related]
10. [Effect of MCNU on growth kinetics of human plasma cell lines--in comparison with melphalan].
Ohnaka T; Ohno T; Kanoh T; Uchino H
Nihon Ketsueki Gakkai Zasshi; 1987 Aug; 50(5):971-7. PubMed ID: 3434146
[No Abstract] [Full Text] [Related]
11. L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line.
Brox LW; Gowans B; Belch A
Cancer Res; 1980 Apr; 40(4):1169-72. PubMed ID: 7357546
[TBL] [Abstract][Full Text] [Related]
12. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
13. Melphalan-induced DNA cross-linking in human melanoma cells and phytohaemagglutinin-stimulated lymphocytes in relation to intracellular drug content and cellular levels of glutathione.
Hansson J; Edgren M; Ehrsson H; Lewensohn R; Ringborg U
Anticancer Res; 1987; 7(1):97-104. PubMed ID: 3566189
[TBL] [Abstract][Full Text] [Related]
14. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
15. Interpreting cell cycle effects of drugs: the case of melphalan.
Lupi M; Cappella P; Matera G; Natoli C; Ubezio P
Cancer Chemother Pharmacol; 2006 Apr; 57(4):443-57. PubMed ID: 16195878
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines.
Drucker L; Afensiev F; Radnay J; Shapira H; Lishner M
Anticancer Drugs; 2004 Jan; 15(1):79-84. PubMed ID: 15090747
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
19. In vitro evidence for homologous recombinational repair in resistance to melphalan.
Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
